Holocene Advisors LP Makes New Investment in Zoetis Inc. (NYSE:ZTS)

Holocene Advisors LP bought a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 567,146 shares of the company’s stock, valued at approximately $110,809,000. Holocene Advisors LP owned approximately 0.13% of Zoetis as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter worth approximately $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis in the third quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the 3rd quarter valued at $33,000. Quarry LP boosted its stake in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the period. Finally, Fortitude Family Office LLC grew its position in Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after purchasing an additional 222 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.8 %

Shares of ZTS stock opened at $175.25 on Monday. The firm has a market capitalization of $79.07 billion, a PE ratio of 32.94, a price-to-earnings-growth ratio of 2.69 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The stock has a fifty day moving average of $183.83 and a two-hundred day moving average of $180.97.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the company earned $1.36 EPS. As a group, research analysts expect that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is currently 32.52%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Piper Sandler upped their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Eleven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $220.80.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.